Clinical Trial Search

Primary: Change From Baseline in Best-Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants — 7.1; 4.6; 5.5; 13.0 ETDRS letters…

Primary: Change in Oxygenation Index (OI) From Baseline to Day 7 of Treatment — -5.3; -6.6 Index — p=0.735

Primary: Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI) — -25.45; -18.95 Percentage change of score

Primary: Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 70.6; 66.7; 84.6; 62.5 percentage of participants

Primary: Number of Participants With AEs and SAEs — 14; 5; 14; 6 Participants

Primary: Number of Participants Who Were Responders (CR, VGPR, or PR) on Day 28 With Low Cumulative Steroid Exposure — 41 Participants

Primary: Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3 — -1.8; -1.6; -1.5; -2.0 score on a scale

Primary: Number of Participants Experiencing Treatment-emergent Adverse Events — 4; 9; 12 Participants

Primary: Number of Participants With Solicited Local and Systemic ARs — 74; 75; 75; 74 Participants

Primary: Ability of PD-L1 to Predict Response — 0.377 Youden index

Primary: Incidence of Treatment Emergent Adverse Events — 23; 43 Participants

Primary: Number of Participants With Adverse Events (AEs) — 20 Participants

Primary: Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) - Cohorts 1 and 2 Pooled — 99.0; 99.0 Percentage of participants

Primary: Overall Response Rate (ORR) in Participants With HER2-negative MBC (Part A and Part B) — 35; 5 percentage of participants